Justin Ferdinandus: BrECADD is better tolerated than eBEACOPP for patients with advanced Hodgkin Lymphoma

Justin Ferdinandus, Resident Physician at University Hospital Cologne, shared on X:

“HD21 results now finally published in The Lancet:

BrECADD is better tolerated and more efficient than eBEACOPP as PET-guided treatment for patients with adv. Hodgkin Lymphoma!”